Brought to you by 
ProGenTech closes its $21mm Series C venture round
May 2008
Executive Summary
ProGenTech (developing nucleic acid purification systems) has raised $21mm through the closing of its Series C venture round. New investors Bay City Capital and DT Capital led the financing.
Deal Industry
- Biotechnology
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Research, Analytical Equipment & Supplies
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ProGenTech closes its $21mm Series C venture round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice